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Atherosclerosis complicated by thromboembolism is the
main cause of obstructive arterial disease in the legs.
Two studies from West Germany suggest that antiplate-
let drugs may slow the progress of atherosclerosis in leg
arteries and prevent occlusive thrombosis under some
circumstances. The same agents may also reduce the risk
of rethrombosis after successful vascular repair in the
femoropopliteal region; in one trial, aspirin decreased
the incidence of reocclusion after thromboendarterec-
tomy and, in another, the combination of aspirin and
dipyridamole was effective after bypass with synthetic
material. Antithrombotic drugs are used in most centers
after percutaneous transluminal angioplasty, but there
is no definite evidence for their need. Thus, it appears
that in contrast to cardiac and cerebrovascular disease,
The most common cause of obstructive arterial disease in
the lower limbs is slowly progressive atherosclerosis, often
complicated by thrombosis. Other types of degenerative or
inflammatory arteriopathy that may also impede the blood
supply to the legs are less frequent (Table I). In this review,
we focus on the problems of secondary prevention and treat-
ment of peripheral arterial disease due to thrombosis on
atheromatous lesions. In addition, the management and pre-
vention of arterial embolism will be discussed.
Antithrombotic Drugs in the Secondary
Prevention of Atherosclerosis and
Thrombosis in the Leg Arteries
The importance of platelets and platelet-derived sub-
stances and the role of fibrin in arterial thrombogenesis is
emphasized in another review (1) in this symposium. From
these concepts, both anticoagulant and antiplatelet drugs
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few efforts have been made to determine the true value
of antithrombotic therapy in peripheral arterial disease.
The management of acute thromboembolism in the
legs requires a multidisciplinary approach. Depending
on the type (embolic or thrombotic), length and local-
ization of the arterial occlusion, surgical (embolectomy,
thromboendarterectomy, peripheral bypass surgery) or
nonsurgical (systemic fibrinolysis or local thrombolytic
therapy with or without balloon angioplasty) treatment
is preferred. The importance of nonsurgical therapeutic
approaches may become even greater in elderly patients
with a poor operative risk. This review discusses the
available therapeutic modalities in acute and chronic
peripheral thromboembolic arterial disease.
(J Am Coil CardioI1986;8:98B-103B)
could theoretically slow down the course of the thrombotic
components in the progression of occlusive arterial disease.
However, the preventive potential of antithrombotic drugs
has been tested far less in peripheral arterial disease than in
ischemic coronary and cerebral disease. The relatively be-
nign evolution of atherosclerosis in the legs largely accounts
for this neglect. The reduced life expectancy in these patients
is mainly due to excess cardiac mortality; the risk of a leg
amputation is relatively low and the threat remote. In ad-
dition, the capricious natural history of the arterial lesions
and the clinical symptoms require strictly controlled studies
to distinguish between spontaneous evolution and drug ef-
fects.
Oral anticoagulants. Thrombosis is only the final step
of a long evolution. Therefore, long-term oral anticoagu-
lation is unlikely to represent a spectacular advance in the
prevention or progression of peripheral arterial occlusive
disease. In fact, a few trials (2-4) have shown a favorable
trend, but their design and size do not allow a definite
conclusion. A prospective study (5) was performed in The
Netherlands in patients suffering from intermittent claudi-
cation. All the selected patients were initially on oral an-
ticoagulant therapy for at least 6 months. They were then
randomly assigned to switch to placebo or to continue the
vitamin K antagonist. The trial was stopped prematurely
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Table 1. Etiology of Peripheral Arterial Occlusive Disease in
the Legs
Degenerative arteriopathy
Atherosclerosis
Miinckeberg's medial sclerosis
MedIal cystic degeneration
Fibromuscular dysplasia
Inflammatory arteriopathy
Thromboangiitis oblIterans (Buerger's disease)
Arteritis associated With connective tissue disease
Systemic gIant cell arteritis
Takayasu's disease
Arterial thrombosis
Idiopathic or immunologic (lupus anticoagulant or heparin-induced
thrombocytopenia)
Peripheral arterial embolism
Arterial trauma
Drug-induced or spontaneous arterial spasm
because of a significantly greater number of deaths in the
placebo group. These favorable results were apparently not
confirmed in a second controlled but still unpublished Dutch
trial (6), which showed no benefit of anticoagulants on walk-
ing distance until claudication, ankle systolic pressure, isch-
emic symptoms or amputation rate.
Antiplatelet agents. To date, only few data are available
to suggest a beneficial effect of antiplatelet drugs on the
progression of atherosclerosis and the occurrence of its
thrombotic complications in patients with obstructive pe-
ripheral arterial disease. Three hundred patients with a ste-
nosis of the femoral artery were randomized by Schoop et
a1. (7) to receive daily either 1 g of aspirin, 1 g of aspirin
combined with 225 mg of dipyridamole or placebo; they
were followed up for 4 years. The occlusion rate was lower
in the two groups treated with the active drugs, but the
combination was not superior to the administration of aspirin
alone. In addition, antiplatelet therapy did not prevent fem-
oral artery thrombosis in diabetic and hypertensive patients.
Recently, Hess et a1. (8) reported a placebo-controlled, dou-
ble-blind, 2 year trial in 199 patients with arteriographically
studied evolution of peripheral atherosclerosis. Progression
of the disease was most pronounced in the placebo group,
less so in the aspirin-treated group (I g daily) and least of
all in the aspirin-dipyridamole-treated group (1 g, 225 mg
daily). In contrast with the results of Schoop et a1. (7),
patients who smoked and those with hypertension benefited
most from active treatment.
Retrospective data accumulated from several (published
and unpublished) double-blind studies on the effect of ke-
tanserin in patients with intermittent claudication seem to
suggest a decrease in cardiovascular complications with this
novel serotonin antagonist. An international multicenter trial
is currently studying this hypothesis prospectively on a large
scale.
Antithrombotic Drugs in the
Prevention of Thrombosis After Peripheral
Arterial Surgery and Percutaneous
Transluminal Angioplasty
Prevention after thromboendarterectomy. Bollinger
and Brunner (9) recently reported the final results of a pro-
spective study of 120 patients who were followed up for 2
years after a successful endarterectomy in the femoropop-
liteal region. All patients received warfarin for the initial 2
postoperative weeks. They were then randomized into three
treatment groups for prophylaxis of reocclusion: aspirin (1
g daily), aspirin-dipyridamole (1 g, 225 mg daily) or an
oral anticoagulant (warfarin). The cumulative patency rate
at 2 years was 84% for the aspirin group, 76% for the
aspirin-dipyridamole group and only 58% for the warfarin-
treated patients. Both antiplatelet regimens were significantly
superior to warfarin, but the level of hypocoagulability
induced by warfarin was probably insufficient. However,
endarterectomy in the femoropopliteal region has largely
been abandoned by most surgeons in favor of bypass sur-
gery.
Prevention after bypass surgery. Because Dacron grafts
in the aortoiliac region have a high long-term patency rate,
demonstration of a beneficial effect of antithrombotic agents
would require a huge number of patients. For reconstruction
to the popliteal, tibial or peroneal arteries, autologous veins,
human umbilical veins or polytetrafluoroethylene prostheses
(PTFE grafts) are used. Thrombosis of these bypass grafts
during the first postoperative month is generally a result of
defective surgical technique or a precarious runoff. Late
occlusion, in contrast, is related to excessive proliferation
of the neointima along the inner wall of the graft followed
by thrombosis. To prevent this complication, some surgeons
prescribe an oral anticoagulant for the first postoperative
months. In some patients with very precarious runoff, life-
long warfarin treatment is recommended. However, this
practice is based on personal clinical experience rather than
on controlled trials. One study (10) suggests that the com-
bination of aspirin and dipyridamole reduces (p < 0.05) the
risk of occlusion of prosthetic femoropopliteal grafts.
Prevention after percutaneous transluminal angio-
plasty. In a large majority of centers that practice balloon
catheter peripheral angioplasty, either anticoagulants or an-
tiplatelet agents are administered to reduce the number of
early reocclusions. Intake of antiplatelet drugs can be started
I or 2 days before the actual procedure. This usage dates
from the very first days of the technique and is based on
the expectation that any lesion inflicted to the intima will
induce a rapid adhesion of platelets followed by thrombus
formation. To our knowledge, no clinical trial has addressed
the role of antithrombotic treatment in the prevention of
early reocclusion after angioplasty in the peripheral arteries.
Even if this tradition of early antithrombotic prophylaxis
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appears acceptable, the value of a long-term antithrombotic
strategy needs assessment.
Management of Acute Arterial
Thromboembolism in the Legs
Irrespective of whether an acute arterial occlusion is due
to thrombosis or embolism, a number of urgent measures
are to be taken. The ischemic leg is placed in a position of
about 15° dependency to avoid further impairment of cap-
illary perfusion. Direct heating of the cold leg and me-
chanical trauma are avoided. Heparin treatment is initiated
at a therapeutic dosage to prevent extension of thrombosis
or recurrent embolism. Further therapeutic measures will
depend on whether the acute occlusion is caused by em-
bolism in a healthy artery or thromboembolism in an ath-
eromatous artery. A proposal of a decision-making pathway
in acute thromboembolism of leg arteries is presented in
Figure I.
Arterial embolism in healthy arteries. This is the pre-
dominant type in young patients with atrial fibrillation. The
embolus is removed with the Fogarty catheter, usually under
local anesthesia. The success rate in terms of limb salvage
is about 90% (11), the best results being obtained in patients
subjected to early embolectomy (that is, within 8 hours).
Leg edema may occur after successful revascularization as
a result of transudation of fluid across the capillary mem-
brane, the permeability of which is increased by hypoxia.
This complication may induce a compartment syndrome and
lead to further damage of the muscle, nerves and vessels.
Fasciotomy may be required. Anticoagulation is continued
after embolectomy unless the source of the embolus is dis-
covered and eradicated.
Thromboembolism in atheromatous arteries. Most of
the acute arterial thromboses and many of the emboli are
superimposed on atheromatous plaques in an already im-
paired arterial circulation. The same general measures are
taken and, in many cases, the Fogarty procedure just de-
scribed (II) will be tried without delay. However, the short-
and long-term success rate of thromboembolectomy in these
conditions is considerably lower than that for an arterial
embolus in a healthy artery. If the Fogarty procedure fails
or is not advisable, localized endarterectomy with throm-
bectomy or vascular reconstruction may be attempted de-
pending on the arteriographic findings.
Thrombolytic therapy. If a surgical intervention is con-
sidered impractical for technical reasons (multiple emboli
in an already compromised circulation) or because of the
poor general condition of the patient, systemic or local
thrombolytic therapy can be considered followed by anti-
thrombotic therapy. The ability to restore blood flow in
acutely occluded arteries by systemic administration of
thrombolytic agents in various treatment schemes has been
amply demonstrated in the past two decades (12-14). The
success rate seems to depend on the delay between the acute
event and the initiation of therapy, although this point is
not established in all series. Hemorrhagic complications due
to the systemic lytic state induced by streptokinase or uro-
kinase are not uncommon. A more fibrin-specific throm-
bolytic agent like tissue-type plasminogen activator has only
recently been introduced for clot-selective thrombolysis in
a variety of thromboembolic conditions (15), including acutely
or subacutely thrombosed peripheral arteries and bypass
grafts (16). This new agent may represent an attractive al-
ternative to both conventional systemic and local throm-
bolytic therapy.
Local thrombolysis with low dose streptokinase has been
used in the last few years in patients with poor general
condition or in subjects with difficult surgical access. The
method was initially proposed by Dotter et al. (17), who
infused streptokinase in a dose of 5,000 IU/h through a
catheter placed in the immediate vicinity of the clot. The
procedure was later modified (18) so that the catheter was
passed into the proximal part of the occluding thrombus.
Bess et ai. (19) reduced the duration of infusion to a tnax-
imum of 5 hours, thereby avoiding significant activation of
Figure 1. Algorithm for the management of
acute thromboembolism in the lower limbs.
PTA = percutaneous transluminal angio-
plasty.
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the fibrinolytic system and reducing the risk of hemorrhagic
complications. Recanalization was obtained in about 70%
of the cases. and was sustained for I year in 50%. The
technique is applied for progressive lysis of occluded bypass
grafts as well, and less recent thrombi may still be dissolved
(Fig. 2).
"Blue toe" syndrome. A number of patients present
with recurrent pain and ischemia in the toes or fingers, even
though the blood supply through the large arteries appears
intact as shown by normal peripheral pulses and systolic
pressures. This so-called blue toe (or blue finger) syndrome
may be due to obstruction of the microcirculation in patients
with essential or secondary thrombocythemia. The platelets
of these patients aggregate spontaneously in vitro (20). Usu-
ally. the symptoms respond to symptomatic treatment with
aspirin, and skin perfusion improves quickly. The under-
lying cause of the thrombocytosis needs investigation and
adequate treatment. Similar but more lasting symptoms of
distal ischemia are occasionally caused by peripheral mi-
croembolization of atherosclerotic debris or cholesterol em-
boli originating from ulcerated lesions in proximal arteries.
Here, too, antiplatelet drugs may help temporarily. but vas-
cular repair without further delay is usually indicated.
Iatrogenic acute arterial occlusion. The daily use of
intraarterial catheters for diagnostic or therapeutic proce-
dures and for monitoring purposes accounts for an increasing
number of acute arterial occlusions. Early thrombectomy is
the treatment of choice for this complication in adults (21);
in many children, infusion of heparin appears to be sufficient
(22). Prophylaxis with antithrombotic drugs, if indicated,
can normally be stopped after a few days.
Management of Chronic Ischemia of the Legs
Prevention. Secondary prevention of atherosclerosis in
patients with obstructive disease of the leg arteries is not
restricted to the discussion on the usefulness of antithrom-
botic drugs; reducing the risk factors is probably a more
important issue. Thus, for decades, patients with peripheral
arterial disease have been exhorted to abstain from smoking,
to follow an appropriate diet and to have hypertension and
diabetes controlled. Other therapeutic measures including
vascular surgery and angioplasty are, to a large extent, pal-
liative; that is, they try to relieve symptoms or, at very best,
extend the viability of the leg.
Drug treatment. Daily physical exercise has been shown
to markedly increase the walking distance in patients with
claudication (23). On the other hand, drug treatment of
chronic leg ischemia remains a highly controversial issue.
Since the case against vasodilating agents was presented
(24,25), new randomized, placebo-controlled, double-blind
trials with different agents have been published (26-28).
With these substances, characteristics other than vasodila-
tation are stressed (for example, improvement in blood
rheology or cell oxygenation). Also, antithrombotic drugs
were tested for their ability to relieve symptoms of chronic
ischemia. For instance, in a Japanese trial (29) the anti-
platelet agent ticlopidine appeared to significantly decrease
the number and extent of ischemic ulcers due to athero-
sclerosis and thromboangiitis obliterans. Recently, ketan-
serin was suggested to improve substantially the walking
distance and the calf blood flow in patients with claudication
(30), but these data have not been confirmed (31).
Figure 2. Local thrombolysis of6 week
old femoral occlusion. A catheter tip
is advanced into the proximal end of
the clot where streptokinase is infused
(5,000 IV/h). The sequence of angio-
grams shows complete reperfusion of
the femoral artery.
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Patients with (severely) handicapping claudication and
those with more advanced stages of ischemia should undergo
arteriography to select for each of them the optimal treatment
modality. A very brief review is given here.
Reconstructive vascular surgery. Many of the patients
who undergo vascular surgery have multisegmental arterial
occlusive disease. The proximal lesion is repaired first either
by aortoiliac endarterectomy or, more commonly, by aor-
tofemoral bypass grafting. The operative mortality of aor-
toiliac surgery is low (I to 2 %), and the long-term patency
rate fairly high (85% at 5 years and 65% at IO years) (32,33).
Surgical repair of a femoropopliteal occlusion is normally
restricted to patients with severe ischemia (rest pain, skin
ulcers) and selected patients with multilevel disease who
receive an aortofemoral graft simultaneously (34). The long-
term results of femoropopliteal bypass surgery depend on
the extent of the arterial disease (distal runoff) and the ma-
terial used for the graft. A higher patency rate is obtained
with autologous veins (75% at 5 years) than with synthetic
materials (35,36). Distal bypasses to the tibial arteries have
a 5 year patency rate of 55% and a limb salvage rate of
73% if autologous veins can be used (37,38). In poor risk
patients and other selected cases, alternative surgical pro-
cedures such as a profundaplasty or so-called extraanatomic
bypasses may be preferred.
Percutaneous transluminal angioplasty. The tech-
nique originally proposed by Dotter and Judkins (39) be-
came popular after the development of the modified Griint-
zig double lumen catheter (40). Short isolated lesions are
the ideal indication for a balloon procedure. The immediate
success rate is greater than 90% in the iliac and more than
80% in the femoropopliteal region; late patency rates of
approximately 85 and 75%, respectively, have been pub-
lished (35,41,42). The most common complications are lo-
cal hematoma at the puncture site and distal embolization,
which rarely requires urgent surgical intervention. The method
may have a theoretical advantage in younger patients in
whom vascular surgery can be postponed for a number of
years. For longer lesions, a combination of local throm-
bolysis with low dose streptokinase and percutaneous trans-
luminal angioplasty can be used, as already described.
Miscellaneous procedures. The value of lumbar sym-
pathectomy in patients with obstructive arterial disease of
the legs remains disputed, even though this intervention
has been practiced for almost six decades. In some centers,
it is still used in conjunction with aortofemoral grafting to
improve the distal perfusion. Others advocate it to (tem-
porarily ?) augment skin perfusion in patients with severe
ischemia in whom vascular repair appears impractical; they
hope in this way to relieve rest pain and accelerate healing
of small skin ulcers. However, unequivocal evidence that
sympathectomy is effective in these two conditions is scarce.
Systemic thrombolytic therapy with streptokinase has also
been used in patients with chronic arterial obstruction, se-
vere ischemia and poor operative prognosis (14,43). At
present, the practice of local thrombolysis combined with
angioplasty is increasing, but no properly controlled study
comparing the two types of streptokinase administration is
yet available (44). Other proteases such as brinase (45),
ancrod (46) and hyaluronidase (47) have been injected into
patients with severe ischemia without convincing results.
Data on the infusion of prostaglandin E, (48) and prosta-
cyclin (49,50) are conflicting. In a controlled study (51),
relief of rest pain was noted.
Many years ago Lassen et al. (52) reported a successful
attempt to treat patients with gangrenous foot ulcers by
increasing the systemic arterial pressure with sodium chlo-
ride and mineralocorticoids. However, increasing the blood
pressure in aged atherosclerotic patients is not devoid of
risk, and this therapy has been restricted to ischemic ulcers
in young patients with Buerger's disease (53).
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